Drug Interaction Report
1 drug interaction and 6 additional warnings found for the following 2 drugs:
- Lisraya (brepocitinib)
- ublituximab
Drug interactions
Major drug interactions
Major:ublituximab brepocitinib
Applies to: ublituximab, Lisraya (brepocitinib)
Using ublituximab together with brepocitinib may increase the risk of serious infections.
Talk to your doctor if you have any questions or concerns.
Of particular concern is an infection known as progressive multifocal leukoencephalopathy (PML), which is a rare but serious viral infection of the brain that may lead to disability and death.
Your doctor may already be aware of the risks but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications.
Let your doctor know if you develop signs and symptoms of infection such as:
- fever
- chills
- sore throat
- shortness of breath
- blood in phlegm
- weight loss
- yellow skin
- severe fatigue
- diarrhea
- vomiting
- body aches
- pain or burning during urination
Also, seek immediate medical attention if you experience:
- progressive weakness on one side of the body
- clumsiness of limbs
- disturbance of vision
- confusion
- changes in thinking, memory, and personality
These may be early symptoms of PML.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:Food/Lifestyle brepocitinib
Applies to: Lisraya (brepocitinib)
Brepocitinib may be taken with or without food.
Chemical substances in cigarette smoke may reduce the blood levels of brepocitinib, which may make the medication less effective.
Tell your doctor if you smoke, or if you start or stop smoking during treatment, as this may affect how well the medication works.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
5 potential interactionsApplies to: 5 conditions, including Liver Disease, Infection, Immunodeficiency, Renal Dysfunction, and Infectious Hepatitis.
Immunodeficiency
Moderate:ublituximab
Ublituximab has a moderate potential interaction with Immunodeficiency.
Ublituximab has been associated with serious, including life-threatening or fatal, bacterial and viral infections. Delay treatment in patients with active infection until resolution. Monitor the levels of quantitative serum immunoglobulins during treatment, especially in patients with opportunistic or recurrent infections, and after discontinuation of therapy until B-cell repletion. For patients with low serum immunoglobulins, consult immunology experts before initiating therapy. Consider treatment discontinuation if a patient with low immunoglobulins develops a serious opportunistic infection or recurrent infections, or if prolonged hypogammaglobulinemia requires therapy with IV immunoglobulins.
Infection
Moderate:ublituximab
Ublituximab has a moderate potential interaction with Infection.
Ublituximab has been associated with serious, including life-threatening or fatal, bacterial and viral infections. Delay treatment in patients with active infection until resolution. Monitor the levels of quantitative serum immunoglobulins during treatment, especially in patients with opportunistic or recurrent infections, and after discontinuation of therapy until B-cell repletion. For patients with low serum immunoglobulins, consult immunology experts before initiating therapy. Consider treatment discontinuation if a patient with low immunoglobulins develops a serious opportunistic infection or recurrent infections, or if prolonged hypogammaglobulinemia requires therapy with IV immunoglobulins.
Infectious Hepatitis
Major:ublituximab
Ublituximab has a major potential interaction with Infectious Hepatitis.
Use of ublituximab is contraindicated in patients with active hepatitis b virus (HBV) infection. Reactivation of HBV has been reported with use of ublituximab. Perform HBV screening in all patients prior to therapy. Consult a liver disease expert in patients who are negative for surface antigen (HBsAg) and positive for HB core antibody (HBcAb+), or are carriers of HBV (HBcAb+).
Liver Disease
Moderate:ublituximab
Ublituximab has a moderate potential interaction with Liver Disease.
Ublituximab may cause liver injury. Patients with ALT/AST greater than 3 times the upper limit of normal (3 x ULN) and total bilirubin greater than 2 x ULN are at risk for severe drug-induced liver injury. The effect of moderate to severe liver dysfunction on the pharmacokinetics of ublituximab is unknown. Prior to therapy with ublituximab, assess ALT, AST, alkaline phosphatase, and bilirubin levels. Monitor for signs and symptoms of any drug-induced liver injury during treatment; discontinue therapy if identified.
Renal Dysfunction
Moderate:ublituximab
Ublituximab has a moderate potential interaction with Renal Dysfunction.
The effect of moderate to severe renal dysfunction on the pharmacokinetics of ublituximab is unknown.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.